Toronto – October 12, 2026 -- Profound Medical Corp. expects third-quarter 2026 revenue of $9.8 million to $10.0 million, roughly 45% to 47% above the Bloomberg mean analyst consensus of $6.78 million.
Revenue nearly doubles year over year and almost quadruples sequentially
The preliminary, unaudited range implies growth of approximately 85% to 89% from $5.3 million in the third quarter of 2025. Compared with $2.5 million in the second quarter of 2026, revenue is expected to rise approximately 292% to 300%.
The Nasdaq- and TSX-listed company expects gross margin to exceed 70% for the quarter, again above that threshold. Profound attributes the margin to progress in its commercial operations and scale.
CEO Menawat credits installed base and new accounts for the surge
Chairman and CEO Arun Menawat called the expected result a historic milestone. He attributed the growth to increased commercial activity across the installed base and new customer accounts. Management says it remains focused on supporting customer adoption and increasing utilization of installed systems.
Figures remain preliminary ahead of November 5 report
Profound cautioned that actual revenue may differ from the preliminary figures. It said the consensus estimates come from third-party analysts and are not endorsed, adopted or controlled by the company. The Bloomberg consensus was compiled as of October 7, 2026 at 9:02 a.m. ET.
The company will publish full third-quarter results after market close on Thursday, November 5, and will host a conference call at 4:30 p.m. ET to review the results and business developments.